Currently, the efforts of state authorities in the fields of pharmaceuticals and healthcare are also aimed at implementing the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030 (hereinafter referred to as the “Pharma 2030 Strategy”). One of the goals of the Pharma 2030 Strategy is to increase the share of domestically produced medicinal products in the total consumption volume from 61.8% to 66.6% by 2030. In this regard, measures to support Russian medicinal products manufacturers continue to be implemented.
1. The Ministry of Industry and Trade will establish a support mechanism for Russian medicinal products manufacturers
On September 29, 2025, a draft Resolution of the Government of the Russian Federation “On the Specifics of Providing Subsidies from the Federal Budget to Russian Organizations to Compensate for Part of the Costs of Implementing Projects for the Development of Original Medicinal Products or Expanding Medical Indications for Their Use” (hereinafter referred to as the “Draft Resolution”) was published. The Draft Resolution has been developed in order to implement the Pharma 2030 Strategy.
Procedure for Granting Subsidies
The explanatory note to the Draft Resolution states that, due to the high risks of pharmaceutical products not reaching the market, it is advisable to compensate Russian organizations for the actual costs incurred in conducting the final phase of clinical trials for original medicinal products in key areas preceding:
-
obtaining a marketing authorization; or
-
amending a marketing authorization to expand the indications for medical use.
The Draft Resolution specifies that such costs directly related to conducting the final phase of clinical trials include:
-
Labor costs for employees of the subsidy recipient;
-
Material costs;
-
Costs for the purchase of laboratory equipment;
-
Costs for payment of services (work) provided by third-party organizations.
Subsidies will be granted to Russian organizations based on a subsidy agreement concluded between the Russian organizations and the Ministry of Industry and Trade via the State integrated information system “Electronic Budget”.
Documents for obtaining a subsidy can be submitted within 1 year from the date of obtaining or amending the marketing authorization.
Result of Subsidy Provision
A Russian organization that has received a subsidy must, within 3 years from the date of obtaining or amending the marketing authorization, ensure that the revenue from the sale of the original medicinal products amounts to at least twice the size of the subsidy received.
Subsidy recipients will also be required to confirm the capability for full-cycle production of the original medicinal products, for which the subsidies were received, within the territory of the Russian Federation.
The Ministry of Industry and Trade will verify compliance with the stated objectives. In case of failure to achieve them, the subsidies are subject to return, and the recipient must pay a penalty fee amounting to 1/300 (one three-hundredth) of the Central Bank of Russia’s key rate applied to the subsidy amount for each day starting from the date the subsidy was received.
Conclusions
Funding under the subsidy mechanism is proposed to commence in 2027. It is planned that the maximum subsidy amount for a single project will not exceed 250 million rubles. At the same time, the number of projects of a single Russian organization eligible for cost reimbursement through the subsidy is unlimited.
The adoption of the Draft Resolution will increase the volume of investments by domestic pharmaceutical enterprises in the development of new pharmaceutical products. However, to launch the mechanism, it is necessary to identify the key areas requiring the development of original medicinal products. According to the explanatory note, such work is already being carried out by the relevant state authorities.
2. Federal Corporation for the Development of Small and Medium Enterprises Expands Support Measures for Organizations in Priority Sectors
On October 2, 2025, the Federal Corporation for the Development of Small and Medium Enterprises announced on its official website a twofold increase in the maximum amount of preferential leasing financing for small businesses in priority sectors. The amount has been increased from 100 to 200 million rubles.
Express Leasing
An express leasing product was also launched for small businesses in priority sectors. It can be provided for a term of 13 to 48 months to acquire equipment costing between 1 and 15 million rubles from a verified pool of suppliers. Limited liability companies (LLCs) where individuals directly own more than 75% of the shares in the charter capital are eligible to receive funding under these terms.
Leasing Financing
Financing for enterprises in priority sectors is provided at preferential rates:
-
6% for Russian equipment
-
8% for foreign equipment
The minimum equipment cost for small enterprises in priority sectors is:
-
3 million rubles, with a down payment from 10%, and
-
500 thousand rubles, with a down payment from 20% under the express leasing program.
Conclusions
These support measures will also assist Russian medicinal products manufacturers in promptly obtaining the necessary equipment to expand or modernize their own production facilities.